多部门医院药物消费的药物流行病学分析作为医疗质量管理的一个要素和评估进口替代的基础

Q3 Medicine
O. Zhukova, O. V. Ruina, M. Khazov, T. M. Konyshkina, E. A. Rodin, D. K. Lipatov
{"title":"多部门医院药物消费的药物流行病学分析作为医疗质量管理的一个要素和评估进口替代的基础","authors":"O. Zhukova, O. V. Ruina, M. Khazov, T. M. Konyshkina, E. A. Rodin, D. K. Lipatov","doi":"10.17749/2070-4909/farmakoekonomika.2022.046","DOIUrl":null,"url":null,"abstract":"Objective: pharmacoepidemiological analysis of medication list used in a multidepartmental hospital.Material and methods. The material for the analysis was the costs of medications for the reporting period of 2017–2018. We used the tools of ABC/VEN analysis and import substitution assessment. The assessment of import substitution in a medical organization was carried out in comparison of 2018 with 2017 by the change in costs for various pharmacotherapeutic groups of medications in two segments (domestic and foreign production) in percentage terms.Results. The results of the analysis revealed, that the antibiotics are the largest volume of the cost structure for various pharmacotherapeutic groups: 18.8% in 2017 and 15.6% in 2018. The analysis of the medication list used in a medical organization, regarding to the production segment, showed that in 2017 22.6% was spent on domestic medications. In 2018, this indicator increased by 15.2% and amounted to 37.8%. The correct, regular distribution of groups V, E, N in groups A, B, C was revealed. More than 80% of group A consists of medications from group V of all monetary costs and the share of medication belonging to group N is less than 3%. In total, the cost of medications of groups V and E is more than 90%.Conclusion. The use of these methods allows to optimize the costs of medications provision for therapeutic and diagnostic processes and to improve pharmaceutical diseases therapy. In 2018, compared to 2017, there is a redistribution of the cost structure for medications towards an increase in the share of Russian-made medications. Given the lower cost of Russian medications compared to imported analogues, this approach will allow in the future to save the money of medical organizations with no deterioration in the quality of treatment. ","PeriodicalId":36464,"journal":{"name":"Farmakoekonomika","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pharmacoepidemiological analysis of medication consumption in a multidepartmental hospital as an element of medical care quality management and the basis for assessing import substitution\",\"authors\":\"O. Zhukova, O. V. Ruina, M. Khazov, T. M. Konyshkina, E. A. Rodin, D. K. Lipatov\",\"doi\":\"10.17749/2070-4909/farmakoekonomika.2022.046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: pharmacoepidemiological analysis of medication list used in a multidepartmental hospital.Material and methods. The material for the analysis was the costs of medications for the reporting period of 2017–2018. We used the tools of ABC/VEN analysis and import substitution assessment. The assessment of import substitution in a medical organization was carried out in comparison of 2018 with 2017 by the change in costs for various pharmacotherapeutic groups of medications in two segments (domestic and foreign production) in percentage terms.Results. The results of the analysis revealed, that the antibiotics are the largest volume of the cost structure for various pharmacotherapeutic groups: 18.8% in 2017 and 15.6% in 2018. The analysis of the medication list used in a medical organization, regarding to the production segment, showed that in 2017 22.6% was spent on domestic medications. In 2018, this indicator increased by 15.2% and amounted to 37.8%. The correct, regular distribution of groups V, E, N in groups A, B, C was revealed. More than 80% of group A consists of medications from group V of all monetary costs and the share of medication belonging to group N is less than 3%. In total, the cost of medications of groups V and E is more than 90%.Conclusion. The use of these methods allows to optimize the costs of medications provision for therapeutic and diagnostic processes and to improve pharmaceutical diseases therapy. In 2018, compared to 2017, there is a redistribution of the cost structure for medications towards an increase in the share of Russian-made medications. Given the lower cost of Russian medications compared to imported analogues, this approach will allow in the future to save the money of medical organizations with no deterioration in the quality of treatment. \",\"PeriodicalId\":36464,\"journal\":{\"name\":\"Farmakoekonomika\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Farmakoekonomika\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.046\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmakoekonomika","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

目的:对某多科室医院用药清单进行药物流行病学分析。材料和方法。分析的材料是2017-2018年报告期间的药物费用。我们使用了ABC/VEN分析和进口替代评估工具。以2018年和2017年为对照,对某医疗机构的进口替代进行评估,以国内和国外生产两个细分市场的各类药物治疗组的成本变化百分比进行比较。分析结果显示,抗生素在各药物治疗组的成本结构中占比最大,2017年为18.8%,2018年为15.6%。对某医疗机构使用的药品清单进行分析,就生产环节而言,2017年国内药品支出占22.6%。2018年,该指标增长15.2%,达到37.8%。揭示了V、E、N组在A、B、C组中的正确规律分布。在所有货币费用中,A组80%以上由V组药物组成,N组药物所占比例不足3%。总而言之,V组和E组的药物费用超过90%。这些方法的使用可以优化用于治疗和诊断过程的药物提供的成本,并改进药物疾病治疗。与2017年相比,2018年的药物成本结构进行了重新分配,增加了俄罗斯制造的药物的份额。鉴于俄罗斯药品与进口类似物相比成本较低,这种做法将来将使医疗机构在不降低治疗质量的情况下节省资金。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacoepidemiological analysis of medication consumption in a multidepartmental hospital as an element of medical care quality management and the basis for assessing import substitution
Objective: pharmacoepidemiological analysis of medication list used in a multidepartmental hospital.Material and methods. The material for the analysis was the costs of medications for the reporting period of 2017–2018. We used the tools of ABC/VEN analysis and import substitution assessment. The assessment of import substitution in a medical organization was carried out in comparison of 2018 with 2017 by the change in costs for various pharmacotherapeutic groups of medications in two segments (domestic and foreign production) in percentage terms.Results. The results of the analysis revealed, that the antibiotics are the largest volume of the cost structure for various pharmacotherapeutic groups: 18.8% in 2017 and 15.6% in 2018. The analysis of the medication list used in a medical organization, regarding to the production segment, showed that in 2017 22.6% was spent on domestic medications. In 2018, this indicator increased by 15.2% and amounted to 37.8%. The correct, regular distribution of groups V, E, N in groups A, B, C was revealed. More than 80% of group A consists of medications from group V of all monetary costs and the share of medication belonging to group N is less than 3%. In total, the cost of medications of groups V and E is more than 90%.Conclusion. The use of these methods allows to optimize the costs of medications provision for therapeutic and diagnostic processes and to improve pharmaceutical diseases therapy. In 2018, compared to 2017, there is a redistribution of the cost structure for medications towards an increase in the share of Russian-made medications. Given the lower cost of Russian medications compared to imported analogues, this approach will allow in the future to save the money of medical organizations with no deterioration in the quality of treatment. 
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Farmakoekonomika
Farmakoekonomika Medicine-Health Policy
CiteScore
1.70
自引率
0.00%
发文量
43
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信